Acquired by Sanofi in May 2023
PRVB - Provention Bio, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Red Bank,
United States
Type: Equity
PRVB price evolution
PRVB
| (in millions $) | 31 Jan 2023 | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $44.04 | $102.38 | $57.88 | $74.91 |
| Short term investments | $120.96 | $83.14 | $26.64 | $10.13 |
| Net receivables | $1.36 | |||
| Inventory | $1.23 | |||
| Total current assets | $174.65 | $190.43 | $90.31 | $91.79 |
| Long term investments | $1.01 | $11.61 | $28.32 | |
| Property, plant & equipment | $2.53 | $2.35 | $2.31 | $2.24 |
| Goodwill & intangible assets | $59.56 | |||
| Total noncurrent assets | $62.21 | $3.48 | $14.05 | $30.67 |
| Total investments | $120.96 | $84.15 | $38.25 | $38.45 |
| Total assets | $236.86 | $193.91 | $104.35 | $122.46 |
| Current liabilities | ||||
| Accounts payable | $6.76 | $3.79 | $5.66 | $7.24 |
| Deferred revenue | $18.39 | $8.02 | $7.28 | $8.03 |
| Short long term debt | ||||
| Total current liabilities | $90.39 | $25.12 | $25.15 | $27.05 |
| Long term debt | $23.47 | $23.78 | $0.52 | $0.56 |
| Total noncurrent liabilities | $24.62 | $24.03 | $0.52 | $1.21 |
| Total debt | $23.91 | $23.78 | $0.52 | $0.56 |
| Total liabilities | $115.01 | $49.14 | $25.67 | $28.25 |
| Shareholders' equity | ||||
| Retained earnings | -$405.64 | -$372.36 | -$343.73 | -$314.04 |
| Other shareholder equity | -$0.65 | -$0.89 | -$0.84 | -$0.71 |
| Total shareholder equity | $121.85 | $144.77 | $78.68 | $94.21 |
| (in millions $) | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $44.04 | $78.19 | $102.29 | $39.16 |
| Short term investments | $120.96 | $16.92 | $19.53 | $46.21 |
| Net receivables | $1.36 | |||
| Inventory | $1.23 | |||
| Total current assets | $174.65 | $101.1 | $126.55 | $86 |
| Long term investments | $32.02 | |||
| Property, plant & equipment | $2.53 | $2.38 | $1.84 | |
| Goodwill & intangible assets | $59.56 | |||
| Total noncurrent assets | $62.21 | $34.52 | $1.97 | |
| Total investments | $120.96 | $48.94 | $19.53 | $46.21 |
| Total assets | $236.86 | $135.62 | $128.52 | $86 |
| Current liabilities | ||||
| Accounts payable | $6.76 | $3.55 | $7.57 | $1.77 |
| Deferred revenue | $18.39 | $7.11 | ||
| Short long term debt | ||||
| Total current liabilities | $90.39 | $22.79 | $16.73 | $3.84 |
| Long term debt | $23.47 | $0.59 | $0.71 | |
| Total noncurrent liabilities | $24.62 | $2.1 | $0.71 | |
| Total debt | $23.91 | $0.59 | $0.71 | |
| Total liabilities | $115.01 | $24.89 | $17.45 | $3.84 |
| Shareholders' equity | ||||
| Retained earnings | -$405.64 | -$292.07 | -$177.64 | -$79.06 |
| Other shareholder equity | -$0.65 | -$0.14 | -$0.01 | |
| Total shareholder equity | $121.85 | $110.73 | $111.07 | $82.16 |
| (in millions $) | 31 Dec 2022 | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $10.81 | $0.76 | $0.75 | $0.58 |
| Cost of revenue | $0.51 | |||
| Gross Profit | $10.3 | $0.76 | $0.75 | $0.58 |
| Operating activities | ||||
| Research & development | $25.53 | $16.34 | $16.58 | $17.36 |
| Selling, general & administrative | $24.31 | $13.49 | $14 | $12.31 |
| Total operating expenses | $50.47 | $29.83 | $30.58 | $29.66 |
| Operating income | -$40.17 | -$29.08 | -$29.83 | -$29.08 |
| Income from continuing operations | ||||
| EBIT | -$38.83 | -$28.38 | -$29.69 | -$29.02 |
| Income tax expense | -$6.34 | -$7.06 | ||
| Interest expense | $0.78 | $0.26 | ||
| Net income | ||||
| Net income | -$33.28 | -$28.63 | -$29.69 | -$21.97 |
| Income (for common shares) | -$33.28 | -$28.63 | -$29.69 | -$21.97 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $12.89 | $1.4 | ||
| Cost of revenue | $0.51 | |||
| Gross Profit | $12.38 | $1.4 | ||
| Operating activities | ||||
| Research & development | $75.8 | $69.63 | $66.36 | $36.36 |
| Selling, general & administrative | $64.11 | $47.35 | $33.33 | $8.01 |
| Total operating expenses | $140.54 | $116.97 | $99.69 | $44.37 |
| Operating income | -$128.16 | -$115.58 | -$99.69 | -$44.37 |
| Income from continuing operations | ||||
| EBIT | -$125.92 | -$115.43 | -$99.1 | -$43.28 |
| Income tax expense | -$13.39 | -$1 | -$0.52 | |
| Interest expense | $1.04 | |||
| Net income | ||||
| Net income | -$113.56 | -$114.43 | -$98.58 | -$43.28 |
| Income (for common shares) | -$113.56 | -$114.43 | -$98.58 | -$43.28 |
| (in millions $) | 31 Dec 2022 | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 |
|---|---|---|---|---|
| Net income | -$33.28 | -$28.63 | -$29.69 | -$21.97 |
| Operating activities | ||||
| Depreciation | $0.79 | $0.13 | $0.12 | $0.12 |
| Business acquisitions & disposals | -$15 | |||
| Stock-based compensation | $9.21 | $3.3 | $3.2 | $3.31 |
| Total cash flows from operations | -$7.97 | -$23.97 | -$28.44 | -$15.03 |
| Investing activities | ||||
| Capital expenditures | -$0.37 | -$0.2 | -$0.23 | |
| Investments | -$35.9 | -$46.03 | $9.6 | |
| Total cash flows from investing | -$51.27 | -$46.23 | -$0.23 | $9.6 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.91 | $90.98 | $11.63 | $2.15 |
| Net borrowings | $23.71 | |||
| Total cash flows from financing | $0.91 | $114.69 | $11.63 | $2.15 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$58.34 | $44.5 | -$17.03 | -$3.28 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Net income | -$113.56 | -$114.43 | -$98.58 | -$43.28 |
| Operating activities | ||||
| Depreciation | $1.16 | $0.35 | $0.06 | |
| Business acquisitions & disposals | -$15 | |||
| Stock-based compensation | $19.03 | $11.84 | $13.22 | $2.84 |
| Total cash flows from operations | -$75.41 | -$95.39 | -$76.34 | -$36.06 |
| Investing activities | ||||
| Capital expenditures | -$0.8 | -$0.96 | -$1.11 | |
| Investments | -$72.33 | -$30.14 | $26.29 | -$46.25 |
| Total cash flows from investing | -$88.13 | -$31.1 | $25.17 | -$46.25 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $105.67 | $102.38 | $114.29 | $62.94 |
| Net borrowings | $23.71 | |||
| Total cash flows from financing | $129.38 | $102.38 | $114.29 | $62.94 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$34.15 | -$24.1 | $63.13 | -$19.37 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 87.67M |
| Revenue | $12.89M |
|---|---|
| EBITDA | -$124.77M |
| EBIT | -$125.92M |
| Net Income | -$113.56M |
| Revenue Q/Q | 1.41K% |
| Revenue Y/Y | 824.37% |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | 1.40 |
| Cash/Share | 0.50 |
| EPS | -$1.30 |
|---|---|
| ROA | -69.08% |
| ROE | -103.36% |
| Debt/Equity | 0.94 |
|---|---|
| Net debt/EBITDA | -0.57 |
| Current ratio | 1.93 |
| Quick ratio | 1.92 |